Furthermore, we compared the therapeutic effects of Everolimus and Nivolumab on different subgroups of patients with advanced ccRCC, the results showed that in population of WDR72 High and PBRM1-MUT, the HR for OS between two treatment groups is 1.53 (0.66-3.55), and in WDR72 Low and PBRM1-WT subgroup, the HR for OS is 1.17 (0.73-1.88). Here, PBRM1 is linked to nonpapillary renal cell carcinoma.